Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines
Autor
Gurwith, Marc
Condit, Richard C.
Excler, Jean-Louis
Robertson, James S.
Kim, Denny
Fast, Patricia E.
Drew, Stephen
Wood, David
Klug, Bettina
Whelan, Mike
Moore, Tamala Mallett
Khuri-Bulos, Najwa
Smith, Emily R.
Chen, Robert T
Kochhar, Sonali
Institución
Resumen
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral
vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of
such vaccines. The standardized and structured assessment provided by the template would also help to
contribute to improved communication and support public acceptance of licensed live-attenuated viral
vaccines.